Table 1 Demographic and clinicopathological characteristics of 1079 patients with UPS [n (%)]
Characteristic | Total (n = 1079) | Training (n = 755) | Validation (n = 324) | P value |
|---|---|---|---|---|
Age/year | 0.616 | |||
≤ 73 | 699 (64.8%) | 485 (64.2%) | 214 (66.0%) | |
≥ 74 | 380 (35.2%) | 270 (35.8%) | 110 (34.0%) | |
Sex | 0.291 | |||
Female | 465 (43.1%) | 317 (42.0%) | 148 (45.7%) | |
Male | 614 (56.9%) | 438 (58.0%) | 176 (54.3%) | |
Race | 0.316 | |||
White | 897 (83.1%) | 631 (83.6%) | 266 (82.1%) | |
Black | 90 (8.4%) | 57 (7.5%) | 33 (10.2%) | |
Other | 92 (8.5%) | 67 (8.9%) | 25 (7.7%) | |
Tumor site | 0.431 | |||
Extremities | 752 (69.7%) | 524 (69.4%) | 228 (70.4%) | |
Trunk | 258 (23.9%) | 178 (23.6%) | 80 (24.7%) | |
Head/face/neck | 69 (6.4%) | 53 (7.0%) | 16 (4.9%) | |
Tumor size/cm | 0.723 | |||
≤ 5.0 | 388 (36.0%) | 274 (36.3%) | 114 (35.2%) | |
5.1–10.0 | 383 (35.5%) | 269 (35.7%) | 114 (35.2%) | |
10.1–15.0 | 173 (16.0%) | 115 (15.2%) | 58 (17.9%) | |
≥ 15.1 | 135 (12.5%) | 97 (12.8%) | 38 (11.7%) | |
Extension | 0.427 | |||
Superficial | 269 (24.9%) | 195 (25.8%) | 74 (22.8%) | |
Deep | 620 (57.5%) | 433 (57.4%) | 187 (57.8%) | |
NOS | 190 (17.6%) | 127 (16.8%) | 63 (19.4%) | |
T stage | 0.781 | |||
T1 | 388 (36.0%) | 274 (36.3%) | 114 (35.2%) | |
T2 | 691 (64.0%) | 481 (63.7%) | 210 (64.8%) | |
N stage | 0.966 | |||
N0 | 1047 (97.0%) | 732 (97.0%) | 315 (97.2%) | |
N1 | 32 (3.0%) | 23 (3.0%) | 9 (2.8%) | |
M stage | 0.34 | |||
M0 | 1003 (93.0%) | 706 (93.5%) | 297 (91.7%) | |
M1 | 76 (7.0%) | 49 (6.5%) | 27 (8.3%) | |
Grade | 0.726 | |||
I + II | 141 (13.1%) | 96 (12.7%) | 45 (13.9%) | |
III | 350 (32.4%) | 250 (33.1%) | 100 (30.9%) | |
IV | 588 (54.5%) | 409 (54.2%) | 179 (55.2%) | |
Surgery | 0.194 | |||
No/unknown | 63 (5.8%) | 39 (5.2%) | 24 (7.4%) | |
Yes | 1016 (94.2%) | 716 (94.8%) | 300 (92.6%) | |
Radiation | 0.231 | |||
No/unknown | 380 (35.2%) | 275 (36.4%) | 105 (32.4%) | |
Yes | 699 (64.8%) | 480 (63.6%) | 219 (67.6%) | |
Chemotherapy | 0.709 | |||
No/unknown | 865 (80.2%) | 608 (80.5%) | 257 (79.3%) | |
Yes | 214 (19.8%) | 147 (19.5%) | 67 (20.7%) |